Please use this identifier to cite or link to this item:
|Scopus||Web of Science®||Altmetric|
|Title:||Pharmacotherapies for cannabis use disorders: Clinical challenges and promising therapeutic agents|
Le Foll, B.
|Citation:||Substance Use Disorders: From Etiology to Treatment, 2020 / Nadar, M.A., Hurd, Y.L. (ed./s), vol.258, Ch.13, pp.355-372|
|Publisher Place:||Cham, Switzerland|
|Series/Report no.:||Handbook of Experimental Pharmacology; 258|
|Suzanne Nielsen, Pamela Sabioni, Linda Gowing, and Bernard Le Foll|
|Abstract:||This chapter reviews pharmacotherapies that have been trialled for cannabis dependence, identifying those that warrant further research and those of little or uncertain value. A diverse range of medicines have been tested, representing a broad range of pharmacological strategies. These include tetrahydrocannabinol preparations, various types of antidepressant, anxiolytics, a glutamatergic modulator and the neuropeptide oxytocin. Cannabinoid agonists warrant further research. For the FAAH inhibitor PF-04457845, oxytocin, varenicline and gabapentin, although there is a signal to indicate further research is warranted, these medications do not yet have sufficient evidence to support clinical use, and larger, longer-term trials are needed in representative treatment-seeking populations. Special populations that warrant consideration are those with cannabis dependence and concurrent mental health conditions and those that develop dependence through therapeutic use.|
|Keywords:||Cannabis; Cannabis dependence; Cannabis use disorder; Pharmacotherapy; Treatment|
|Rights:||© Springer Nature Switzerland AG 2019|
|Appears in Collections:||Aurora harvest 4|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.